Accuray (NSDQ:ARAY) said today it won FDA 510(k) clearance for its iDMS data management system designed for sharing data between the company’s treatment delivery platforms.
The Sunnyvale, Calif.-based company said the iDMS system is designed to integrate data from its technology platforms, including the Radixact, TomoTherapy and CyberKnife systems, as well as the company’s Accuray Precision treatment planning and oncology information systems.
The iDMS allows users to store and manage all patient and treatment data across multiple devices to allow for more informed, efficient radiation treatments, Accuray said.
“This most recent clearance reinforces Accuray’s commitment to providing clinicians with options for seamless, fully integrated treatment planning and data management, enhancing department workflow efficiency. The common database will make it possible for clinicians to use any available Accuray treatment system, expanding patient access to the precision and treatment versatility of our advanced radiation therapy systems,” chief commercial officer Lionel Hadjadjeba said in a press release.
Earlier this month, Accuray released data from a prospective study comparing its TomoTherapy intensity-modulated radiation therapy system with Varian Medical‘s (NYSE:VAR), RapidArc radiotherapy system, touting a higher survival rate for patients treated with its TomoTherapy